Radiotherapy for SCLC: Proving the Feasibility of A Higher Dose
High-dose, accelerated radiotherapy brings better 2-year overall survival, with no added toxicity...
Mar 5, 2021
High-dose, accelerated radiotherapy brings better 2-year overall survival, with no added toxicity...
Mar 5, 2021
New indication upgrades drug to first-line therapy based on CROWN results WASHINGTON — The...
Mar 5, 2021
Better OS and PFS, plus greater likelihood of response with combo Combination treatment with...
Mar 5, 2021
This study is aimed to assess the outcomes of radiotherapy. IMN is defined as a regional node similar to the ALN, previous studies have suggested that breast cancer involving IMN has a worse prognosis than that involving ALN...
Mar 5, 2021
In this study, only patients aged 50 years or older with node negative breast cancer were included. In the START-B trial, reducing the overall treatment time from 5 weeks to 3 weeks led to improved disease free survival and...
Mar 5, 2021
Although the potential benefit of additional screening examinations in moderate risk patients (patients with a history of breast cancer in one or two family members) remains unclear. Breast cancer patients with a first degree...
Mar 5, 2021
A breast cancer (BC) patient treated with mastectomy has to decide whether or not to have immediate BR. This study aimed to assess decisional conflict in patients considering immediate breast reconstruction, and to identify...
Mar 5, 2021
In recent decennia, mammography screening has been introduced in many countries. There are ongoing debates on whether screening does more harm than good and on the related optimization of screening strategy. We cannot measure...
Mar 4, 2021
Blinatumomab improves some outcomes in relapse/refractory disease Two trials of...
Mar 4, 2021
Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA-approved as front-line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off-protocol and...
Mar 4, 2021
In this phase I study, we evaluated the safety, biodistribution and dosimetry of [Zr]Zr-DFO-girentuximab (Zr-girentuximab) PET/CT imaging in patients with suspicion of clear cell renal cell carcinoma (ccRCC).Ten eligible...
Mar 4, 2021
To estimate the cost-effectiveness and value of information of cabozantinib compared to nivolumab in advanced renal cell carcinoma (RCC) patients, who previously failed treatment from a societal perspective in South Korea.A...